Online registration is now closed.  
We will start on-site registration Saturday, May 4 at 7:30 am at the Ritz-Carlton, Tysons Corner

The incidence of inflammatory bowel disease (IBD) continues to rise in the world, and now affects more than 1.6 million Americans. We currently have a better understanding of the pathogenesis of IBD, allowing for the development of new therapies targeting the inflammatory pathways. Hence, the management of this complex disease is in turn becoming complex, where the clinician needs to use evidence-based medicine to personalize the use of the appropriate therapy for each individual patient. Becoming familiar with therapeutic drug monitoring and disease monitoring is essential to maximize the therapeutic benefit of drugs and the chance of maintaining IBD patients in remission and preventing complications. Patients with long standing IBD carry an increased risk of colon cancer, and the IBD therapies available have potential side effects. It is essential for healthcare providers to use current guidelines in prevention and screening of these complications to maximize patients’ health and the quality of care. IBD not only affects the gastrointestinal tract, but also several organ systems, often requiring a multidisciplinary approach to the patients involving several medicine specialties, colorectal surgery and radiology as well as nutrition support. Other auto-immune and inflammatory diseases of the GI tract, such as eosinophilic esophagitis, celiac disease, microscopic colitis, auto-immune pancreatitis, appendicitis and diverticulitis, often present a challenge to the healthcare providers in terms of diagnosis, management and disease monitoring. New guidelines in the management of these diseases have been recently published and need to be judiciously applied and individualized to patients. The purpose of this symposium is to provide up-to-date information on the pathogenesis of the disease process, as well as evidence-based recommendations on the management and monitoring of IBD and other inflammatory and autoimmune disorders. Through this course, the gap between state-of-the-art practice and current practices will be closed to provide a high quality, comprehensive, multidisciplinary approach to patients with IBD. We believe this approach will improve the quality of care provided to patients, decrease the risk of complications and morbidity, and reduce the overall burden of IBD on the patient and society.

1. Implement quality measures in IBD
2. Utilize different biologics in treatment of IBD
3. Examine the role of therapeutic drug monitoring in IBD and apply it in clinical practice
4. Manage IBD in pregnancy
5. Apply the new recommendations for the management of colon dysplasia in IBD
6. Recognize and manage rheumatological complications in IBD
7. Recognize and manage hepatobiliary complications in IBD
8. Implement nutrition therapy and support in IBD
9. Diagnose and manage primary sclerosing cholangitis and cholangiocarcinoma
10. Apply a multidisciplinary approach when treating IBD and its complications

Registration Fees:

• Physician $125
• Resident and Fellow $75
• Physician Assistant $75
• Nurse Practitioner $75
• Nurse $75
• Allied Health Professional $75
• Patient $75

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC) and the American Academy of PAs (AAPA) to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 6.25 Interprofessional Continuing Education (IPCE) credits for learning and change.